Zachary D. Crees, MD

Zachary D. Crees, MD

Assistant Professor of Medicine

Address:
Division of Oncology
Mail Stop 8007-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110 (practice location)

Admin:
Shannon Dobbs
dobbss@wustl.edu

Clinical Interests
  • Multiple Myeloma
  • MDS and Leukemia
  • Lymphoma
  • CAR-T
  • Gene and cellular immunotherapies
  • Stem cell transplant
  • Stem cell mobilization
Research

I serve as the Principal Investigator or Co-Principal Investigator on seven clinical trials:

  • present-2024
    Phase 1 Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (NCT06547112)
    PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • present-2024
    Phase 1 Multicenter, Open-Label Study of UB-VV111 in Combination with Rapamycin in Relapsed or Refractory CD19+ B-Cell Malignancies (NCT06528301)
    PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • present-2023
    Phase 1 Trial Evaluating Motixafortide(CXCR4 inhibitor) Alone and in Combination with Natalizumab (VLA-4 inhibitor) to Mobilize Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease (NCT05618301)
    PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • present-2020
    Phase II Trial Evaluating Flotetuzumab (MGD006) for Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation (NCT04582864)
    Co-PI’s: Dr. John DiPersio and Dr. Matthew Christopher, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • 2024-2023
    Zuma-25: A Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) Chimeric Antigen Receptor T-Cell Therapy in Adult Patients with Relapsed/Refractory Rare B-Cell Malignancies (NCT05537766)
    PI: Zachary Crees, Washington University School of Medicine, Division of Oncology, St. Louis, MO
  • 2023-2020
    Phase Ib Trial Evaluating Kymriah (tisagenlecleucel) + Efineptakin Alfa (NT-I7) for Relapsed/Refractory Large B-cell Lymphoma
    Co-PI’s: Dr. John DiPersio and Dr. Armin Ghobadi, Washington University School of Medicine, Division of Oncology St. Louis, MO
  • 2023-2020
    Phase II Trial Evaluating Uproleselan (GMI-1271) as GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (NCT04682405)
    Co-PI’s: : Dr. Geoffrey Uy and Dr. Keith Stockerl-Goldstein, Washington University School of Medicine, Division of Oncology, St. Louis, MO
Profiles (publications)
WU Physician Bio

Biosketch

Education

  • 2015-2011: MD (with honors), University of Illinois College of Medicine, Rockford, IL
  • 2011-2008: BS in Biology (summa cum laude), University of Colorado College of Liberal Arts and Sciences, Denver, CO

Post-Graduate Training

  • 2022-2020: Chief Fellow, Hematology and Oncology, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO
  • 2020-2019: Fellow, Hematology and Oncology, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO
  • 2019-2018: Chief Resident, Internal Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO
  • 2018-2016: Resident, Internal Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO
  • 2016-2015: Intern, Internal Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO

Academic Positions

  • present-2022: Assistant Professor of Medicine, Division of Oncology, Section of Hematologic Malignancies, Washington University School of Medicine, St. Louis, MO
  • present-2022: Assistant Clinical Director, Center for Gene and Cellular Immunotherapy (CGCI), Division of Oncology, Section of Hematologic Malignancies, Washington University School of Medicine, St. Louis, MO

University & Hospital Appointments

  • 2022-2019: Program Evaluation Committee, Washington University, Heme/Onc Fellowship Program
  • 2022-2019: Clinical Competency Committee, Washington University, Heme/Onc Fellowship Program
  • 2019-2018: Housestaff Liaison Committee, Washington University, Medicine Residency Program
  • 2019-2018: Resident Wellness Committee, Washington University, Medicine Residency Program
  • 2019-2018: Clinical Competency Committee, Washington University, Medicine Residency Program
  • 2019-2018: Balance in Medicine Committee, Washington University, Medicine Residency Program

Board Certification

  • 2022: American Board of Internal Medicine, Medical Oncology
  • 2022: American Board of Internal Medicine, Hematology
  • 2018: American Board of Internal Medicine, Internal Medicine

Honors & Awards

  • 2024: Oral Presentation, American Society of Hematology Annual Meeting
  • 2022: Hanna Jean Khoury Outstanding Graduate Award, Washington University Hematology-Oncology Fellowship
  • 2021: Siteman Investment Program Funding Awarded for Uproleselan Study
  • 2021: Abstract Achievement Award, American Society of Hematology
  • 2021: Oral Presentation, American Society of Hematology Annual Meeting
  • 2021: Knowlton Incentive for Excellence Award, The Foundation for Barnes-Jewish Hospital
  • 2020: Teaching Fellow of the Year, Washington University School of Medicine
  • 2018: Karl-Flance Teaching Award, Washington University School of Medicine
  • 2017: American College of Physicians Abstract Competition Winner 3rd place – Clinical Vignette
  • 2016: Intern of the Month, Washington University, Internal Medicine Residency Program
  • 2015: James Scholar Award for Outstanding Research
  • 2015: American College of Physicians National Abstract Competition Winner
  • 2014: Gold Humanism Honor Society
  • 2014: Alpha Omega Alpha (AOA) Honor Medical Society

Professional Societies

  • present-2019: American Society for Transplantation and Cellular Therapy
  • present-2019: American Society of Clinical Oncology
  • present-2019: American Society of Hematology